These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 17637478

  • 1. Vascular effects of PPARgamma activators - from bench to bedside.
    Marx N, Walcher D.
    Prog Lipid Res; 2007 Nov; 46(6):283-96. PubMed ID: 17637478
    [Abstract] [Full Text] [Related]

  • 2. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM, Schiffrin EL.
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [Abstract] [Full Text] [Related]

  • 3. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
    Marx N, Duez H, Fruchart JC, Staels B.
    Circ Res; 2004 May 14; 94(9):1168-78. PubMed ID: 15142970
    [Abstract] [Full Text] [Related]

  • 4. PPARgamma and atherosclerosis.
    Staels B.
    Curr Med Res Opin; 2005 May 14; 21 Suppl 1():S13-20. PubMed ID: 15811195
    [Abstract] [Full Text] [Related]

  • 5. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
    Mughal RS, Warburton P, O'Regan DJ, Ball SG, Turner NA, Porter KE.
    Clin Exp Pharmacol Physiol; 2009 May 14; 36(5-6):478-86. PubMed ID: 19673929
    [Abstract] [Full Text] [Related]

  • 6. Can PPARgamma agonists have a role in the management of obesity-related hypertension?
    Chetty VT, Sharma AM.
    Vascul Pharmacol; 2006 Jul 14; 45(1):46-53. PubMed ID: 16713364
    [Abstract] [Full Text] [Related]

  • 7. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V, Viswanathan P.
    Curr Opin Investig Drugs; 2006 Oct 14; 7(10):891-7. PubMed ID: 17086933
    [Abstract] [Full Text] [Related]

  • 8. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
    Blaschke F, Caglayan E, Hsueh WA.
    Endocrinol Metab Clin North Am; 2006 Sep 14; 35(3):561-74, ix. PubMed ID: 16959586
    [Abstract] [Full Text] [Related]

  • 9. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B, Fonseca V.
    Vascul Pharmacol; 2006 Jul 14; 45(1):29-35. PubMed ID: 16777491
    [Abstract] [Full Text] [Related]

  • 10. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
    Gacka M, Adamiec R, Dobosz T, Szymaniec S, Bednarska-Chabowska D.
    Przegl Lek; 2004 Jul 14; 61(12):1436-9. PubMed ID: 15850344
    [Abstract] [Full Text] [Related]

  • 11. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.
    Yang J, Zhang D, Li J, Zhang X, Fan F, Guan Y.
    Clin Sci (Lond); 2009 Jan 14; 116(1):17-26. PubMed ID: 19037881
    [Abstract] [Full Text] [Related]

  • 12. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer?
    Luconi M, Cantini G, Serio M.
    Steroids; 2010 Jan 14; 75(8-9):585-94. PubMed ID: 19900469
    [Abstract] [Full Text] [Related]

  • 13. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation.
    Belvisi MG, Hele DJ, Birrell MA.
    Eur J Pharmacol; 2006 Mar 08; 533(1-3):101-9. PubMed ID: 16458290
    [Abstract] [Full Text] [Related]

  • 14. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
    Duan SZ, Usher MG, Mortensen RM.
    Circ Res; 2008 Feb 15; 102(3):283-94. PubMed ID: 18276926
    [Abstract] [Full Text] [Related]

  • 15. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
    Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X.
    Metabolism; 2007 Oct 15; 56(10):1396-401. PubMed ID: 17884451
    [Abstract] [Full Text] [Related]

  • 16. Glutathione peroxidase 3 mediates the antioxidant effect of peroxisome proliferator-activated receptor gamma in human skeletal muscle cells.
    Chung SS, Kim M, Youn BS, Lee NS, Park JW, Lee IK, Lee YS, Kim JB, Cho YM, Lee HK, Park KS.
    Mol Cell Biol; 2009 Jan 15; 29(1):20-30. PubMed ID: 18936159
    [Abstract] [Full Text] [Related]

  • 17. Drug insight: thiazolidinediones and diabetic nephropathy--relevance to renoprotection.
    Panchapakesan U, Chen XM, Pollock CA.
    Nat Clin Pract Nephrol; 2005 Nov 15; 1(1):33-43. PubMed ID: 16932362
    [Abstract] [Full Text] [Related]

  • 18. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
    Demerjian M, Man MQ, Choi EH, Brown BE, Crumrine D, Chang S, Mauro T, Elias PM, Feingold KR.
    Exp Dermatol; 2006 Mar 15; 15(3):154-60. PubMed ID: 16480422
    [Abstract] [Full Text] [Related]

  • 19. Peroxisome proliferator-activated receptor gamma as a novel therapeutic target in asthma.
    Park SJ, Lee YC.
    J Asthma; 2008 Mar 15; 45(1):1-8. PubMed ID: 18259989
    [Abstract] [Full Text] [Related]

  • 20. Role of PPARgamma in macrophage biology and atherosclerosis.
    Zhang L, Chawla A.
    Trends Endocrinol Metab; 2004 Dec 15; 15(10):500-5. PubMed ID: 15541649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.